Therapeutic vaccine against the precancerous condition of the cervix
Australians have developed a therapeutic vaccine against papillomavirus infection
According to the local unit of the Associated Press (New HPV vaccine to treat infection), the development of the drug, released by the biotech company Coridon, was led by Ian Frazer.
Currently, Gardasil and Cervarix vaccines produced by Merck and GlaxoSmithKline pharmaceutical companies are used to prevent cervical cancer developing against the background of infection with human papillomavirus (HPV), respectively.
The difference between the drug created by Fraser and his colleagues is that it not only protects against HPV infection, but also stimulates the immune response to an infection already present in the body. The effectiveness of vaccination was confirmed by the results of preclinical animal tests. Currently, the developers are preparing to conduct clinical trials with the participation of patients.
According to Fraser, many women are already carriers of HPV, so they cannot reduce the risk of developing cervical cancer by using Gardasil or Cervarix for vaccination. He also suggested that the mechanism of action of the new drug will be used to create a vaccine against herpesvirus infection.
Oncogenic HPV strains are responsible for 70 percent of cervical cancers, as well as about 60 percent of mouth and pharyngeal cancers. At the same time, in most cases, the infection passes over time without any treatment. For the discovery of the role of papillomaviruses in the development of cervical cancer, German scientist Harald zur Hausen was awarded the Nobel Prize in Physiology or Medicine in 2008.
Portal "Eternal youth" http://vechnayamolodost.ru
29.03.2012